Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
Pazopanib plus lapatinib may leads to higher overall survival compared with lapatinib (low certainty).
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
Pazopanib plus lapatinib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
Pazopanib plus lapatinib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
The review found no eligible studies for this question.
Pazopanib showed no clear difference in overall survival compared with lapatinib (low certainty).
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).
It is very uncertain whether pazopanib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).
It is very uncertain whether pazopanib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
It is very uncertain whether pazopanib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
Pazopanib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
The review found no eligible studies for this question.
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).